Ashish Juvekar
Incyte (United States)(US)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, BRCA gene mutations in cancer, DNA Repair Mechanisms, Cytokine Signaling Pathways and Interactions, NF-κB Signaling Pathways
Most-Cited Works
- → Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer(2012)475 cited
- → Phosphoinositide 3-Kinase Regulates Glycolysis through Mobilization of Aldolase from the Actin Cytoskeleton(2016)386 cited
- → Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer(2016)246 cited
- → Bortezomib Induces Nuclear Translocation of IκBα Resulting in Gene-Specific Suppression of NF-κB–Dependent Transcription and Induction of Apoptosis in CTCL(2011)96 cited
- → Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment(2020)95 cited
- → Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion(2016)92 cited
- → Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy(2020)88 cited
- → Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice(2011)84 cited
- → Gene-Specific Repression of Proinflammatory Cytokines in Stimulated Human Macrophages by Nuclear IκBα(2010)54 cited
- → Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseases(2020)45 cited